X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

This is not a video game: New TV ad showcases the destruction of a cancer cell by immune system

By Robert Zirkelbach  |    February 5, 2017
Today, as part of our new advertising and public affairs initiative, GOBOLDLY™, we are excited to announce the premier of our newest TV advertisement, Cells, which highlights innovative...   Read More

The 20-year journey yielding a new weapon against cancer

By Andrew Powaleny  |    January 10, 2017
Developing new medicines is a long, complex process. On average, it takes at least 10-12 years for a new medicine to complete the journey from initial discovery to becoming part of a patient’s...   Read More

Significant progress fighting cancer: Death rate has dropped 25 percent

By Holly Campbell  |    January 9, 2017
Cancers have long been one of the most devastating and complex disease areas facing patients. But thanks in part to innovative advancements in treatments and early detection, the cancer death rate...   Read More

Video: Translating science into new medicines

By Andrew Powaleny  |    December 12, 2016
Researchers and scientists at America’s biopharmaceutical companies and around the globe work every day to translate science into new treatments and cures to allow patients to live longer,...   Read More

Building on the promise of personalized medicine

By Andrew Powaleny  |    November 16, 2016
PhRMA’s member companies are on the leading edge of personalized medicine development– an area that is transforming health care, improving patient outcomes and creating health system efficiencies....   Read More

ICER puts hard-fought progress in non-small cell lung cancer treatment at risk

By Holly Campbell  |    September 1, 2016
Lung cancer is the leading cause of cancer death among men and women in the United States, and each year, tens of thousands of Americans are diagnosed with the most common form, non-small cell...   Read More

ICYMI: NYT explores how immunotherapy is revolutionizing cancer care

By Holly Campbell  |    August 1, 2016
In case you missed it, this past weekend The New York Times published a series exploring the use of immunotherapy to combat cancer. Cell Wars features a primer on these new therapies and patient...   Read More

ICYMI: ICER solicits feedback on its value assessment framework

By Randy Burkholder  |    July 28, 2016
In case you missed it, the Institute for Clinical and Economic Review (ICER) is seeking suggestions to improve its value assessment framework prior to its re-release in 2017. For the past two...   Read More

What they are saying about ICER’s scoping document for non-small cell lung cancer

By Holly Campbell  |    July 11, 2016
The Institute for Clinical and Economic Review (ICER) has set its sights on a new target: life-saving treatments for advanced non-small cell lung cancer (NSCLC). ICER’s latest draft scoping...   Read More

Burden on patients: Access to medicines in health insurance exchange plans

By Allyson Funk  |    June 23, 2016
Access to prescription medicines is critical to help patients manage their chronic conditions and maximize quality of life. Unfortunately, even with insurance coverage, many patients still...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates